Moteur de recherche d’entreprises européennes

Financement de l’UE (7 742 500 €) : Propulser la transition vers l’avenir des emballages circulaires, sûrs et durables et des solutions écoconçues pour les dispositifs à usage unique dans les … Hor24/12/2024 Programme de recherche et d'innovation de l'UE « Horizon »

Texte

Propulser la transition vers l’avenir des emballages circulaires, sûrs et durables et des solutions écoconçues pour les dispositifs à usage unique dans les environnements de soins de santé

The healthcare sector is hindered by several barriers that hamper the application of circular economy principles (e.g. the safety restrictions of the domain limit the use of recycled materials due to the need of materials biocompatibility, and safety in products to be used in the human body). Led by a multidisciplinary consortium of 39 partners (plus 13 industry affiliates) from 15 EU countries plus UK and USA, ENKORE aim to tackle challenges and develop an ecoDesign framework that supports the development of safe and environmental compliant devices eco-responsible packaging, which minimize the environmental impact, reduce the carbon footprint, and maximize the use and preservation of resources. The main goal is to connect the design of the medical devices packages with the end-of-life stage, thus the technologies that support circularity are taken into account at the medical device conception stage. ENKORE framework will be validated in 5 Reference Use Cases (RUCs), led by 5 different health regions that bring HPCs and policy maker, 3 large EU hospitals and the reference network for European Regional and Local Health Authorities (EUREGHA). The project developments and RUCs are supported by several associations and NGOs, a packaging manufacturer and a group of SMEs and researchers, specialists in circularity, LCA, social sciences, environment, circularity, and materials. The validation of the framework shall provide evidence to work with policymakers, creating new or revised standards and create tangible/quantitative evidence. Policy making and regulatory engagement will be strongly performed. The methods and tools comprise Environmental and Social Life Cycle Assessment (ELCA/SLCA), Circularity Calculator (CC) and Digital Product Passport (DPP) approaches, which could be adapted during the second stage of the proposal.


Boehringer Ingelheim Pharmaceuticals Inc. ?
Active Ageing Association 185 000 €
Agenzia Regionale Per LA Salute Ed IL Sociale 250 000 €
Baxter R AND D Europe 0,00 €
Boehringer Ingelheim Internationalgesellschaft mbH 0,00 €
Charite - Universitaetsmedizin Berlin 349 000 €
Consorcio Mar Parc de Salut de Barcelona 250 000 €
Dupont DE Nemours (Luxembourg) Sàrl 0,00 €
Eli Lilly AND Company 0,00 €
Enosi Asthenon Elladas 205 000 €
European Regional AND Local Health Authorities ASBL 253 750 €
Fondazione Policlinico Universitario Campus BIO Medico 335 700 €
Forum des Patients Europeens 88 750 €
Fresenius Medical Care Deutschland GmbH 0,00 €
Fundacion Universidad Francisco de Vitoria 229 250 €
Happy Mondays Communication SL 432 500 €
Idryma Technologias Kai Erevnas 206 875 €
Institoyto Bioiatrikis Texnologias 221 500 €
International Solid Waste Association 150 000 €
Johnson & Johnson Medical GmbH 0,00 €
Medtronic Iberica SA 0,00 €
Multimed Engineers Srl 203 125 €
Naucnoistrazivacki Institut Verlab ZA Biomedicinski Inzinjering Medicinske Uredaje I Vjestacku Inteligenciju 192 813 €
Novo Nordisk A/S 0,00 €
Osai Automation System S.p.A. Societa' Benefit 293 750 €
Pfizer Inc. 0,00 €
Politechnika Poznanska 290 238 €
Predictby Research And Consulting SL 498 750 €
Samenwerkende Topklinische Opleidingsziekenhuizen 393 750 €
Servicio Madrileno de Salud 211 875 €
Sofradim Production Sasu 0,00 €
Sterimed Holding 481 250 €
Takeda Pharmaceuticals International AG 0,00 €
Tech Hive Labs Astiki Mi Kerdoskopiki Etaireia 347 500 €
Universidad Politecnica de Madrid 578 125 €
Universita Campus BIO Medico Di Roma 391 250 €
Universiteit Leiden 469 000 €
Uniwersytet Medyczny w Lodzi 233 750 €

https://cordis.europa.eu/project/id/101166707

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, États-Unis.